Acetylcholine release pathway

The **acetylcholine release pathway** refers to the series of molecular events that govern the synthesis, storage, and exocytotic release of the neurotransmitter acetylcholine (ACh) from cholinergic neurons. This process involves high-affinity choline uptake into presynaptic terminals via specific transporters; enzymatic synthesis by choline acetyltransferase using choline and acetyl-CoA as substrates; packaging into synaptic vesicles; calcium-dependent vesicle docking and fusion with the presynaptic membrane upon neuronal depolarization; and subsequent binding to postsynaptic nicotinic or muscarinic receptors. The released ACh is rapidly degraded in the synapse by acetylcholinesterase. Disruption or modulation of this pathway underlies several neurological diseases and is targeted by various toxins (such as botulinum toxin), venoms, enzyme inhibitors used in Alzheimer's disease therapy, and experimental drugs affecting cholinergic signaling[1][2][3][4][5]. **Note:** "Acetylcholine release pathway" describes a biological process rather than a discrete molecular target such as a receptor or enzyme. It is not considered a canonical therapeutic target itself but encompasses multiple targets within its steps—such as choline transporters, SNARE proteins involved in vesicle fusion, voltage-gated calcium channels regulating exocytosis, nicotinic/muscarinic receptors on postsynaptic cells, and enzymes like choline acetyltransferase or acetylcholinesterase. Therefore: *is_target*: false — it is not a single molecule/receptor/enzyme but rather an entire process. *is_incorrect*: true — this entry does not correspond to an individual druggable target but instead refers broadly to a physiological mechanism involving many potential targets. For structured data extraction purposes or drug discovery databases focused on molecular entities ("targets"), each component protein should be listed separately under its own canonical name.

Inhibition of acetylcholine vesicle fusion and release (botulinum toxin) Stimulation of excessive acetylcholine release (black widow spider venom) Inhibition of choline uptake, reducing ACh synthesis and subsequent release Inhibition of acetylcholinesterase to increase synaptic ACh levels